Viking Therapeutics, Inc.

Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued, leaving the big pharma on the sidelines of the obesity dru

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio

In the non-alcoholic steatohepatitis (NASH) space, Novo Nordisk was the star of the 2024 American Association for the Study of Liver Disease meeting with additional data from its Phase III study of se